Abstract:Cutaneous melanoma is a highly aggressive cancer capable of distant and lethal metastatic spread. Recent breakthroughs have come from understanding oncogenic signaling and cancer immunobiology. Targeted therapies successfully block MAPK signaling in BRAFV600e mutant melanoma with remarkably high clinical responses followed by rapid relapse, whereas checkpoint inhibitors activating the immune response induce long-lasting responses, albeit only in a subset of patients. These limitations have driven interest in understanding innate and acquired resistance. Using an immunocompetent genetically-engineered mouse model of BRAF-driven melanoma, which phenocopies the human disease in its development, histopathology, and response to therapy, we focused on the tumor microenvironment (TME), seeking to elucidate resistance mechanisms. Our investigations have revealed that tumor-associated macrophages (TAMs) are a critical component of the TME, predominantly polarized toward a pro-tumoral "M2-like" phenotype, producing immunosuppressive factors and exhibiting extensive immuno-suppressive capabilities suggesting that they might significantly hinder immune responses in the melanoma TME. Seeking to assess their functional importance, we have found that combining conventional strategies with TAMs-reprogramming agents stimulates anti-tumor immune responses, leading to improved survival and responsiveness to standard-of-care therapies. These data highlight the central role played by macrophages in melanoma progression and demonstrate that pharmacologic reprogramming of macrophages represents a new therapeutic modality with the potential to elicit more effective anti-tumor immune responses against this devastating disease. Citation Format: Melanie Tichet, Agnieszka Chryplewicz, Douglas Hanahan. Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl) nr B41.

TAM-tastic: from resistance to resilience in cancer

Targeting conserved TIM3 + VISTA + tumor-associated macrophages overcomes resistance to cancer immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

The Role of TAMs in the Regulation of Tumor Cell Resistance to Chemotherapy

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Decoding the spatiotemporal heterogeneity of tumor-associated macrophages

Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer

Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach

Targeting tumor-associated macrophages to reverse antitumor drug resistance

Targeting of TAMs: can we be more clever than cancer cells?

Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress

Tumour-associated macrophages: versatile players in the tumour microenvironment

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Targeting tumor-associated macrophages for cancer treatment

Abstract B41: Reprogramming immunosuppressive tumor-associated macrophages potentiates standard-of-care therapy in melanoma